Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an update.
Shandong Xinhua Pharmaceutical said its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, has received a Drug Registration Certificate from China’s National Medical Products Administration for its 0.2g Ibuprofen Granules, classified as a Class 3 chemical over-the-counter medicine. The approval, which confirms compliance with national drug registration and quality requirements, enables the subsidiary to commence production and sale of the ibuprofen granules once it meets pharmaceutical quality management standards, potentially strengthening the group’s OTC pain-relief portfolio and revenue base in the Chinese market.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer operating in the generic drugs segment, with a focus on chemical medicines. Through wholly owned subsidiaries such as Shandong Zibo Xincat Pharmaceutical Company Limited, it develops and produces over-the-counter and prescription products for the domestic Chinese healthcare market.
Average Trading Volume: 1,003,506
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.72B
For detailed information about 0719 stock, go to TipRanks’ Stock Analysis page.